{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T12:10:16Z","timestamp":1756728616652,"version":"3.44.0"},"reference-count":26,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>MiR-9-5p is up-regulated in lupus nephritis (LN) patients and targets Foxo1 that is a protective factor against renal disorders. In the current study, the role of miR-9-5p\/Foxo1 LN progression was assessed and the associated mechanism was explored. The levels of LN-associated miRs were firstly detected in MRL\/lpr mice. Then the effect of miR-9-5p modulation on the viability of SV40 MES 13 cells was detected. MRL\/lpr mice were treated with miR agomirs or antagonists, and effects on renal structure and function were assessed. MiR-9-5p was selected as the potential target, which was up-regulated in MRL\/lpr mice, contributing to the suppressed expression of Foxo1. The modulation of miR-9-5p in vitro influenced the viability of SV40 MES 13 cells. The progression of LN in mice was also associated with the increased level of miR-9-5p and the decreased level of Foxo1. The administration of miR agomirs significantly impaired renal structure and function impairments associated with LN, along with the suppressed expression of Foxo1, while antagonists improved these features by up-regulating Foxo1 level. The current study demonstrated that miR-9-5p showed LN promoting effects, which depended on the inhibition of Foxo1.<\/jats:p>","DOI":"10.33549\/physiolres.935539","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T11:54:37Z","timestamp":1756727677000},"page":"635-643","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of the Progression of lupus Nephritis in MRL\/lpr Mice by Modulating miR-9-5p\/Foxo1 Axis"],"prefix":"10.33549","author":[{"given":"H","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital, Jiujiang, China. Email: www_tngjj12@163.com"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319-323. https:\/\/doi.org\/10.1097\/MAJ.0b013e31827f4ee3","DOI":"10.1097\/maj.0b013e31827f4ee3"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000;160:3136-3140. https:\/\/doi.org\/10.1001\/archinte.160.20.3136","DOI":"10.1001\/archinte.160.20.3136"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Okpechi IG, Ameh OI. Lupus nephritis: An approach to diagnosis and treatment in South Africa. S Afr Med J 2015;105:1071-1074. https:\/\/doi.org\/10.7196\/SAMJ.2015.v105i12.10224","DOI":"10.7196\/samj.2015.v105i12.10224"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Tang Y, Zhang X, Ji L, Mi X, Liu F, Yang L, Qin W. Clinicopathological and outcome analysis of adult lupus nephritis patients in China. Int Urol Nephrol 2015;47:513-520. https:\/\/doi.org\/10.1007\/s11255-014-0903-y","DOI":"10.1007\/s11255-014-0903-y"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2016;55:252-262. https:\/\/doi.org\/10.1093\/rheumatology\/kev311","DOI":"10.1136\/annrheumdis-2014-eular.1113"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Balajkova V, Olejarova M, Moravcova R, Kozelek P, Posmurova M, Hulejova H, Senolt L. Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus? Phys Res 2020;69:339-346. https:\/\/doi.org\/10.33549\/physiolres.934308","DOI":"10.33549\/physiolres.934308"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol 2017;29:241-247. https:\/\/doi.org\/10.1097\/BOR.0000000000000381","DOI":"10.1097\/BOR.0000000000000381"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Imran TF, Yick F, Verma S, Estiverne C, Ogbonnaya-Odor C, Thiruvarudsothy S, Reddi AS, Kothari N. Lupus nephritis: an update. Clin Exp Nephrol 2016;20:1-13. https:\/\/doi.org\/10.1007\/s10157-015-1179-y","DOI":"10.1007\/s10157-015-1179-y"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mej\u00eda JC, Aydintug AO, Chwalinska-Sadowska H, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308. https:\/\/doi.org\/10.1097\/01.md.0000091181.93122.55","DOI":"10.1097\/01.md.0000091181.93122.55"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Schieppati A, Remuzzi G. Novel therapies of lupus nephritis. Curr Opin Nephrol Hypertens 2008;17:156-161. https:\/\/doi.org\/10.1097\/MNH.0b013e3282f4e54d","DOI":"10.1097\/MNH.0b013e3282f4e54d"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Lee SB, Kalluri R. Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl 2010:S22-26. https:\/\/doi.org\/10.1038\/ki.2010.418","DOI":"10.1038\/ki.2010.418"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Yuan XK, Ni PS, Yan ZH, Yu Z, Wang ZZ, Zhang CK, Li FH, Yu XM. Effects of life-long exercise on age-related inflammation, apoptosis, oxidative stress, ferroptosis markers, and NRF2\/KAEP 1\/Klotho Pathway in Rat Kidneys. Physiol Res 2024;73:577-591. https:\/\/doi.org\/10.33549\/physiolres.935290","DOI":"10.33549\/physiolres.935290"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Tili E, Michaille JJ, Calin GA. Expression and function of micro-RNAs in immune cells during normal or disease state. Int J Med Sci 2008;5:73-79. https:\/\/doi.org\/10.7150\/ijms.5.73","DOI":"10.7150\/ijms.5.73"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Vinuesa CG, Rigby RJ, Yu D. Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol 2009;28:112-138. https:\/\/doi.org\/10.1080\/08830180902934909","DOI":"10.1080\/08830180902934909"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Mo W, Jin J, Wang X, Luan W, Yan J, Long X. MicroRNA-206 Contributes to the Progression of Preeclampsia by Suppressing the Viability and Mobility of Trophocytes via the Inhibition of AGTR1. Physiological research 2023;72:597-606. https:\/\/doi.org\/10.33549\/physiolres.935131","DOI":"10.33549\/physiolres.935131"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Liao W, He XJ, Zhang W, Chen YL, Yang J, Xiang W, Ding Y. MiR-145 participates in the development of lupus nephritis by targeting CSF1 to regulate the JAK\/STAT signaling pathway. Cytokine 2022;154:155877. https:\/\/doi.org\/10.1016\/j.cyto.2022.155877","DOI":"10.1016\/j.cyto.2022.155877"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Guo A, Sun Y, Xu X, Xing Q. MicroRNA-30a Targets Notch1 to Alleviate Podocyte Injury in Lupus Nephritis. Immunol Invest 2022;51:1694-1706. https:\/\/doi.org\/10.1080\/08820139.2022.2027440","DOI":"10.1080\/08820139.2022.2027440"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Chafin CB, Reilly CM. MicroRNAs implicated in the immunopathogenesis of lupus nephritis. Clin Dev Immunol 2013;2013:430239. https:\/\/doi.org\/10.1155\/2013\/430239","DOI":"10.1155\/2013\/430239"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Ermakov EA, Kabirova EM, Sizikov AE, Buneva VN, Nevinsky GA. IgGs-Abzymes from the Sera of Patients with Systemic Lupus Erythematosus Hydrolyzed miRNAs. J Inflamm Res 2020;13:681-699. https:\/\/doi.org\/10.2147\/JIR.S258558","DOI":"10.2147\/jir.s258558"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Hong YA, Bae SY, Ahn SY, Kim J, Kwon YJ, Jung WY, Ko GJ. Resveratrol Ameliorates Contrast Induced Nephropathy Through the Activation of SIRT1-PGC-1\u03b1-Foxo1 Signaling in Mice. Kidney Blood Press Res 2017;42:641-653. https:\/\/doi.org\/10.1159\/000481804","DOI":"10.1159\/000481804"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic acids research 2016;44:D457-462. https:\/\/doi.org\/10.1093\/nar\/gkv1070","DOI":"10.1093\/nar\/gkv1070"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology 2012;16:284-287. https:\/\/doi.org\/10.1089\/omi.2011.0118","DOI":"10.1089\/omi.2011.0118"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Gene Ontology Consortium: going forward. Nucleic Acids Res 2015;43:D1049-1056. https:\/\/doi.org\/ 10.1093\/nar\/gku1179","DOI":"10.1093\/nar\/gku1179"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017;12:825-835. https:\/\/doi.org\/10.2215\/CJN.05780616","DOI":"10.2215\/cjn.05780616"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Hakkim A, F\u00fcrnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010;107:9813-9818. https:\/\/doi.org\/10.1073\/pnas.0909927107","DOI":"10.1073\/pnas.0909927107"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"So BYF, Yap DYH, Chan TM. MicroRNAs in lupus nephritis-role in disease pathogenesis and clinical applications. Int J Mol Sci 2021;22. https:\/\/doi.org\/10.3390\/ijms221910737","DOI":"10.3390\/ijms221910737"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T11:54:41Z","timestamp":1756727681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_635.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":26,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935539","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,31]]}}}